A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse [Gynecologic Cancer]
Conclusion
Neither farletuzumab dose met the study’s primary PFS end point. Prespecified subgroup analyses demonstrated that patients with CA-125 levels not more than three times the ULN and patients with higher farletuzumab exposure showed superior PFS and OS compared with placebo.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Vergote, Armstrong, Scambia, Teneriello, Sehouli, Schweizer, Weil, Bamias, Fujiwara, Ochiai, Poole, Gorbunova, Wang, OShannessy, Herzog Tags: Chemotherapy Gynecologic Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Ovarian Cancer | Ovaries | Statistics | Study | Taxotere | Women